Welcome to our dedicated page for PepGen SEC filings (Ticker: PEPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PepGen Inc. filings document the regulatory record of a clinical-stage biotechnology company developing Enhanced Delivery Oligonucleotide therapies for neuromuscular and neurological diseases. Its Form 8-K disclosures cover financial results, corporate presentations, clinical data updates for PGN-EDODM1, FDA-related regulatory matters involving FREEDOM2-DM1, and other business updates tied to its development pipeline.
The company’s proxy materials describe annual meeting matters, director elections, auditor ratification, board structure, executive compensation and stockholder voting mechanics. Other filings address officer appointments, inducement grants, stock-option plans, option repricing, common-stock compensation arrangements and related governance approvals. Together, the filings outline PepGen’s clinical-development disclosures, capital and equity incentive structure, risk-facing regulatory events and public-company governance practices.
PepGen Inc. director Laurie Keating reported a new compensation award on a Form 4. She received a stock option to buy 34,000 shares of PepGen common stock at an exercise price of $1.79 per share, expiring on June 17, 2036.
The option vests in full on the earlier of the first anniversary of the grant date or the date of the next Annual Meeting, as long as she continues serving as a director, unless the board decides otherwise. After this grant, Keating holds options covering 34,000 underlying shares from this award.
PepGen Inc. Chief Technical Officer Kasraian Kasra reported an automatic sale of 1,233 shares of Common Stock on May 21, 2026 at a weighted average price of $1.4107 per share, with individual trades ranging from $1.41 to $1.4541.
According to the disclosure, the shares were sold by the company under a mandatory sell-to-cover provision tied to vested restricted stock units, solely to satisfy minimum statutory tax withholding obligations. The filing states this sale was made under an RSU agreement treated as a binding contract consistent with the Rule 10b5-1 affirmative defense and does not represent a discretionary trade by the insider. Following the transaction, Kasraian Kasra directly holds 50,074 shares of PepGen common stock.
PepGen Inc. furnished an updated corporate presentation outlining clinical progress for its investigational DM1 therapy PGN-EDODM1 and its cash runway. The company highlights its EDO delivery platform, which has shown up to a 98-fold increase in nuclear uptake of oligonucleotides in preclinical models and high levels of splicing correction and myotonia improvement with multiple doses. Early clinical data from the single-ascending-dose study show dose-dependent splicing correction, with 83% of patients at 15 mg/kg achieving more than 20% splicing improvement at Day 28 and robust muscle drug concentrations. Initial multiple-ascending-dose data at 5 mg/kg in the FREEDOM2 trial indicate a favorable safety profile, mean splicing correction of 22.9% excluding one outlier, and promising functional trends, supporting ongoing 10 mg/kg and planned 12.5 mg/kg cohorts. The company states it has a strong cash runway into the second half of 2027 through the FREEDOM2 12.5 mg/kg readout.
PepGen Inc. has filed a shelf registration that permits offers of up to $400,000,000 of common stock, preferred stock, debt securities, warrants and units. Separately, PepGen entered into an at-the-market Sales Agreement with Stifel dated to sell up to $100,000,000 of common stock under the prospectus. The Sales Agreement replaces a prior agreement and terminates the prior sales prospectus; $88,474,029.98 remained available under the prior agreement prior to this filing. The prospectus states proceeds are intended for general corporate purposes, including research and development and clinical programs, with timing and specific allocations to be described in future prospectus supplements.
PepGen Inc. ownership update: Viking Global Investors and related entities report beneficial ownership of 3,482,434 shares of Common Stock, equal to 5.03% of the class based on 69,167,958 shares outstanding as of March 31, 2026.
This Amendment No. 1 removes David C. Ott as a Reporting Person effective March 31, 2026, and confirms the filing parties and their shared voting and dispositive powers over the disclosed shares.
PepGen Inc. reporting persons Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson and Michael Kramarz state beneficial ownership of 4,475,000 shares of Common Stock, representing 6.5%, as of March 31, 2026.
Shares outstanding were reported as 69,167,958 Common Stock as of March 31, 2026 in the Issuer's Form 10-Q. The filing is an amendment to a Schedule 13G/A and is signed on May 15, 2026.
PepGen Inc. reported first quarter 2026 results and development updates for its PGN-EDODM1 program in myotonic dystrophy type 1. The 5 mg/kg cohort of the FREEDOM2-DM1 multiple ascending dose trial showed favorable safety and promising biomarker data, and the 10 mg/kg cohort is fully enrolled with results expected in the second half of 2026.
The company held $132.3 million in cash, cash equivalents and marketable securities as of March 31, 2026, which it believes will fund operations into the second half of 2027. For the quarter, research and development expenses were $13.0 million and general and administrative expenses were $5.9 million, leading to a net loss of $17.8 million, or $(0.26) per share, compared with a net loss of $30.2 million in the prior-year period.
The U.S. FDA placed a partial clinical hold on the FREEDOM2 study related to preclinical pharmacology and toxicology questions; PepGen states the trial’s timing has not been impacted and it is working with the agency to address these questions.
PepGen Inc. reported another quarterly loss as it advances its neuromuscular disease pipeline. For the three months ended March 31, 2026, net loss was $17.8 million, improving from $30.2 million a year earlier, as research and development spending declined.
Research and development expense fell to $13.0 million from $25.4 million, mainly due to lower manufacturing and personnel costs following discontinuation of its DMD program, while general and administrative expense was flat at $5.9 million. Interest income of $1.3 million partially offset operating losses.
The company ended the quarter with $132.3 million in cash, cash equivalents and marketable securities and an accumulated deficit of $378.9 million. Management believes this liquidity will fund currently planned operations into the second half of 2027 while it continues Phase 2 development of lead candidate PGN-EDODM1 for DM1.